Hypothesis

Acute, low‑intensity activation of the TRPV1 channel triggers a calcium‑dependent hormetic cascade that enhances autophagy, mitochondrial biogenesis and insulin sensitivity, whereas persistent TRPV1‑driven CGRP release in an inflammatory milieu drives metabolic dysfunction. Consequently, nonspecific analgesia blunts the beneficial hormetic signal without mitigating the maladaptive pathway, explaining why broad‑spectrum analgesics increase mortality while targeted TRPV1 modulation or senolytic clearance improves healthspan.

Mechanistic rationale

1. TRPV1‑mediated calcium spikes activate CaMKII → CREB → PGC‑1α, promoting mitochondrial oxidative capacity and ROS‑dependent Nrf2 signaling. These effects are dose‑dependent and require transient, sub‑noxious stimuli (e.g., brief capsaicin exposure or mild heat).
2. In aged tissues, senescent cells secrete IL‑6, IL‑1β and PGE₂ that sensitize nociceptors, converting TRPV1 signaling into a chronic, high‑frequency pattern. Sustained calcium influx favors calcineurin/NFAT signaling, which upregulates CGRP secretion from pancreatic islets and adipose tissue, impairing insulin action and promoting fibrosis.
3. Standard analgesics (opioids, NSAIDs) reduce neuronal firing but do not alter the upstream senescent load or the bias between CaMKII/CREB versus calcineurin/NFAT branches; they merely dampen output, thereby removing both protective and harmful signals while adding off‑target toxicity (cardiovascular risk, overdose).
4. Senolytic removal of SASP‑producing cells restores the transient‑signal phenotype, allowing low‑dose TRPV1 agonism to preferentially engage the CaMKII/CREB arm.

Testable predictions

• Prediction 1: In wild‑type mice aged 18 months, intermittent low‑dose capsaicin (0.1 mg/kg, i.p., three times weekly) will increase LC3‑II/I ratio and p62 degradation in skeletal muscle and liver, indicating heightened autophagic flux, whereas continuous capsaicin infusion via osmotic pump will not.
• Prediction 2: The autophagic benefit of intermittent capsaicin will be abolished in mice lacking TRPV1 in sensory neurons (TRPV1‑fl/‑;Advillin‑Cre) or treated with a selective CaMKII inhibitor, confirming dependence on the CaMKII/CREB branch.
• Prediction 3: In a pro‑aging model (e.g., Ercc1‑/‑ Δ7 mice), combining senolytic treatment (dasatinib + quercetin) with intermittent capsaicin will yield additive improvements in glucose tolerance and insulin secretion compared with either intervention alone, while continuous capsaicin will exacerbate hyperglycemia.
• Prediction 4: Pharmacologic blockade of CGRP receptors (olcegepant) will improve metabolic parameters only when administered after senolytic clearance, indicating that CGRP’s detrimental effect is contingent on an inflammatory milieu.
• Prediction 5: Administration of standard analgesics (morphine or celecoxib) to aged mice will not alter autophagic markers but will increase aortic calcification and mortality, recapitulating clinical observations.

Falsifiability

If intermittent capsaicin fails to enhance autophagy or improve metabolic health in any of the above conditions, or if senolytics do not shift the balance toward protective TRPV1 signaling, the hypothesis would be refuted. Conversely, demonstration that broad‑spectrum analgesics directly suppress the CaMKII/CREB pathway independent of off‑target effects would also contradict the claim that their harm is unrelated to pain‑pathway biology.

Implications

This framework reframes analgesic development: rather than seeking global pain suppression, therapies should aim to restore physiological, transient nociceptive signaling (e.g., via timed TRPV1 agonists, low‑level heat therapy, or bioelectrical stimulation) while eliminating the inflammatory drivers that convert it into a maladaptive signal. Such an approach could decouple analgesia from accelerated aging and reconcile the paradox of a pain‑free yet rapidly aging population.